The triple aim promised by healthcare reform-better quality care, greater patient satisfaction, at a lower cost-will play out procedure by procedure, as physicians find ways to deliver better care and ...

Please provide your email address to receive an email when new articles are posted on . The prospective, multinational, investigator-initiated, single-arm, phase 4 HoT-PE trial included adults with ...

The FINANCIAL — Janssen Pharmaceuticals announced the U.S. Food and Drug Administration has approved XARELTO, an oral anticoagulant, for the treatment of deep vein thrombosis and/or pulmonary embolism ...

NEW YORK (AP) — Johnson & Johnson’s Xarelto received an expanded indication as the Food and Drug Administration on Friday approved the blood thinner both to treat and to reduce the risk of recurrence ...

The EINSTEIN-PE Investigators. Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. New England Journal of Medicine. (April 5, 2012) 366;14. The traditional treatment for patients ...

RARITAN, N.J., Sept. 27, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data from the Phase 3 UNIVERSE study showing treatment with XARELTO ® ...

Raritan, NJ (September 8, 2011) — Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD) announced today that the U.S. Food and Drug Administration’s (FDA) Cardiovascular and Renal ...

Chaplin, J. , Akhtari, A. and Lum, W. (2025) Recurrent Deep Vein Thrombosis (DVT) with Negative D-Dimer in a Patient on Rivaroxaban: A Diagnostic Pitfall. Open Journal of Emergency Medicine, 13, ...

In the Prevention of VTE in Acutely ill Patients, Rivaroxaban Compares Favorably with Enoxaparin but Does Not Show a Consistent Net Clinical Benefit MAGELLAN study meets primary efficacy endpoints of ...

The “triple aim” promised by healthcare reform—better-quality care, greater patient satisfaction, at a lower cost—will play out procedure by procedure as physicians find ways to deliver better ...